Search

Displaying results 5111 - 5120 of 10000 in total
  1. Drug

    CV-8102

    go.drugbank.com/drugs/DB19184
    Investigational

    CV-8102 is under investigation in clinical trial NCT03203005 (IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients).

  2. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.

  3. Drug

    Telapristone acetate

    go.drugbank.com/drugs/DB05253
    Investigational

    Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.

  4. Drug

    IRX-2

    go.drugbank.com/drugs/DB05643
    Investigational

    IRX-2 contains a human leukocyte-derived cytokine mixture. It is being investigated to promote or enhance an anti-cancer immune response.

  5. Drug

    ARX517

    go.drugbank.com/drugs/DB23076
    Investigational

    ARX517 is under investigation in clinical trial NCT04662580 (ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer).

  6. Drug

    Fluoroacetic acid F-18

    go.drugbank.com/drugs/DB15202
    Investigational

    Fluoroacetic acid F-18 is under investigation in clinical trial NCT01320787 (18-F-Fluoroacetate as PET Imaging Agent).

  7. Drug

    Isopentane

    go.drugbank.com/drugs/DB16203
    Investigational

    Isopentane is under investigation in clinical trial NCT00752089 (Experimental Dentifrice Remineralization/fluoride Uptake in an in Situ Model).

  8. Drug

    B27PD

    go.drugbank.com/drugs/DB16289
    Investigational

    B27PD is under investigation in clinical trial NCT01195948 (Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis).

  9. Drug

    TCB-008

    go.drugbank.com/drugs/DB18352
    Investigational

    TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.

  10. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

    Synonyms: autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor, an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR